Indaptus Therapeutics, Inc. (INDP): Operating Cash Flow
-$14.82M
Year ended 2025-12-31
-$14.70M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$14.82M | n/m | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | -$12.32M | n/m | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | -$13.41M | n/m | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | -$13.08M | n/m | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | -$11.29M | n/m | 2023-03-17, From 2021-01-01 |
| 2020-12-31 | -$3.32M | n/a | 2022-03-21, From 2020-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | 2025-12-31 | -$14.82M | n/m |
| Soligenix, Inc. (SNGX) | 2025-12-31 | -$10.27M | n/m |
| ProMIS Neurosciences Inc. (PMN) | 2025-12-31 | -$28.12M | n/m |
| Kala Bio, Inc. (KALA) | 2025-12-31 | -$31.99M | n/m |
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | -$8.95M | n/m |
| FibroBiologics, Inc. (FBLG) | 2025-12-31 | -$16.39M | n/m |
| Earth Science Tech, Inc. (ETST) | 2026-03-31 | $1.94M | -55.6% |
| MAIA Biotechnology, Inc. (MAIA) | 2025-12-31 | -$18.84M | n/m |
| Cocrystal Pharma, Inc. (COCP) | 2025-12-31 | -$8.19M | n/m |
Compare INDP, SNGX, PMN, KALA side by side · Screen every company in Pharmaceutical Preparations ↗